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Hemolytic Uremic Syndrome (HUS) 
Background 
1. Definition  
o Triad of  
 Hemolytic anemia (microangiopathic) 
 Thrombocytopenia 
 Renal insufficiency 
 
Pathophysiology 
1. Pathology  
o Proinflammatory process, caused by bacterial toxins or intrinsic factor 
invasion (commonly intestinal mucosa) 
o Infection spreads from intestine to beef in slaughterhouses 
o Toxin causes end organ damage (mesangial cells, renal tubular epithelium, 
etc) 
o Prothrombotic factors cause microangiopathic hemolytic anemia (Coomb's 
negative) 
o Microthrombi, platelet aggregates leading to occlusion of renal arterioles 
and capillaries 
o Possible predisposition familial, genetic or HLA-type 
o 2 forms of disease  
 Diarrhea associated (D+)  
 Most common type 
 Most cases secondary to Shiga toxin-producing E. coli 
(STEC) which may be part of normal flora in cattle, but not 
in humans 
 Non-diarrhea associated (D-) 
2. Incidence/prevalence  
o 8% of infected children will develop HUS 
o Incidence higher in rural areas 
o Outbreaks occur in developing and developed countries 
3. Risk factors  
o Undercooked beef 
o Young age (1-10 yo) 
o Antibiotic use for bloody diarrhea 
o Anti-motility/anti-diarrheal drugs 
o HIV 
o Autoimmune dz 
o Pregnancy 
o Caring for infected cattle 
4. Morbidity/mortality  
o Diarrhea-induced HUS  
 Mortality 9%  
 CNS involvement correlated highly with death 
 ESRD 3% 
 Renal impairment, including hypertension 25% 
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Diagnostics 
1. History and physical exam  
o Prodrome  
 Bloody diarrhea  
 Mainly in children, especially when STEC as pathogen 
 Can be asymptomatic, esp in adults 
o Fever 
o Abdominal cramps 
o Classic triad (after 3-14 d)  
 Anemia 
 Thrombocytopenia 
 Acute renal failure (oliguria, anuria, hypertension) 
o Neuro Sx in 32%  
 Irritability, seizures, altered mental status 
2. Diagnostic testing  
o Stool culture for STEC 
o CBC 
o Haptoglobins (decreased) 
o Peripheral blood smear (fragmented RBCs, burr cells, helmet cells) 
o Reticulocytes (elevated) 
o LDH (increased) 
o Coomb's test (negative) 
o Coagulation components - PT, PTT (usually normal), fibrin degradation 
products (normal) 
o Leukocytosis 
o Thrombocytopenia (<150,000) 
o Renal function tests (azotemia) 
o C-reactive protein (elevated) 
o Urinalysis (hematuria, proteinuria or normal) 
3. Diagnostic "criteria"  
o Clinical triad  
 Microangiopathic anemia 
 Thrombocytopenia 
 Renal failure 
4. Recommendation  
o Stool culture for STEC while having the diarrhea stage (SOR:C)
3,4
  
 
Differential Diagnosis 
1. Other types of dysentery 
2. Henoch-Schonlein purpura  
o Renal disease 
o Purpura but no thrombocytopenia 
o Arthritis 
o Abdominal pain 
3. DIC  
o Low fibrinogen 
o Thrombin time prolonged 
o Low fibrin degradation products (FDP) 
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4. TTP  
o Hemolytic anemia, thrombocytopenia and CNS involvement  
 Occasionally renal failure, making clinical distinction difficult 
o Neurological changes  
 In 90% of TTP and 15% of HUS 
o Acute renal failure and anuria  
 In 2% of TTP and 98% of HUS 
o Protease activity  
 Decreased more in TTP (89% vs 13% in HUS) 
o Protease inhibitor  
 Exists in 51% of TTP and not in HUS 
o Important to distinguish TTP from HUS  
 TTP needs prompt plasma exchange otherwise mortality rate very 
high 
 
Therapeutics 
1. Acute treatment  
o Do not treat with antibiotics or antidiarrheals (SOR:C)
5,6
  
o Fluid and electrolytes  
 Some evidence suggests early rehydration after diarrhea and sodium 
replacement may prevent severe complications 
 Caution to avoid overload of fluids when HUS develops 
 Monitor fluids in/out, weight and vital signs, electrolytes 
o Anemia  
 Replace blood if H&H <6/18 
o Platelets  
 Rarely needed, only if bleeding and <10K 
o Acute renal failure  
 Adjust medication dose 
 Avoid nephrotoxic medications 
 Restrict fluid to insensible loss plus urine output 
 Correct electrolytes 
 Consider dialysis if uremia symptoms present, severe fluid overload, 
electrolyte abnormalities, early dialysis related to better outcome 
o Hypertension  
 Calcium channel blockers  
 1st-line 
 Nifedipine 
 ACE inhibitors  
 2nd-line, controversial data  
 Enalapril 
 Other antihypertensives medication may be considered as well 
o In rare cases when there is CNS involvement, some evidence suggests use 
of plasmapheresis, similar to adult patients with TTP (where CNS 
involvement is a major manifestation) 
o HUS is a reportable disease 
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2. Further management  
o ACE inhibitors  
 Recommended for long-term, but have to be watched for possible 
worsening renal function 
o Monitor platelets 
3. Prevention  
o Avoid ingestion of infected food  
 Once infection occurs, no management proven to prevent 
development of HUS 
 
Follow-Up 
1. Blood pressure monitoring / treatment (ACEi) 
2. Renal function tests  
 
Prognosis 
1. Complications  
o Gastrointestinal  
 Intestinal strictures/perforations 
 Intussusception 
 Pancreatitis 
 Severe colitis 
o Neurologic (rare and may confuse with TTP)  
 Altered mental status 
 Focal neurologic signs 
 Seizures 
o Renal  
 Chronic renal failure 
 Hematuria 
 Hypertension 
 Proteinuria 
o Cardiac  
 Fluid overload 
 Pericarditis due to uremia 
 
Prevention  
1. Avoid eating contaminated / undercooked meat (beef) 
2. Avoid swimming in contaminated/dirty water 
3. Wash hands 
 
Patient Education 
1. http://familydoctor.org/online/famdocen/home/common/kidney/905.printerview.ht
ml 
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